Review article · 2026

From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials

Mansi Verma, Niraj Kumar Singh

Metabolic Brain Disease, 41(1) · Published 18 March 2026 · DOI 10.1007/s11011-026-01793-0

View at the publisherCite this paper

In brief

“From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials” is a 2026 review article by Mansi Verma and Niraj Kumar Singh, published in Metabolic Brain Disease. OpenAlex counts 0 citations as of 15 November 2026. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
0
References
66
Authors
2

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Verma, M., & Singh, N. K. (2026). From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials. Metabolic Brain Disease, 41(1). https://doi.org/10.1007/s11011-026-01793-0

MLA 9

Verma, Mansi, and Niraj Kumar Singh. “From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials.” Metabolic Brain Disease, vol. 41, no. 1, 2026. https://doi.org/10.1007/s11011-026-01793-0.

Chicago

Verma, Mansi and Niraj Kumar Singh. 2026. “From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials.” Metabolic Brain Disease 41 (1). https://doi.org/10.1007/s11011-026-01793-0.

Harvard

Verma, M. and Singh, N. K. (2026) ‘From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials’, Metabolic Brain Disease, 41(1). doi:10.1007/s11011-026-01793-0.

IEEE

M. Verma and N. K. Singh, “From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials,” Metabolic Brain Disease, vol. 41, no. 1, 2026, doi: 10.1007/s11011-026-01793-0.

BibTeX

@article{verma2026from,
  title     = {{From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials}},
  author    = {Verma, Mansi and Singh, Niraj Kumar},
  journal   = {Metabolic Brain Disease},
  year      = {2026},
  volume    = {41},
  number    = {1},
  doi       = {10.1007/s11011-026-01793-0},
  url       = {https://doi.org/10.1007/s11011-026-01793-0}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments

  • Alzheimer's disease
  • Alzheimer's disease therapeutics
  • amyloid-beta
  • tau pathology
  • anti-amyloid monoclonal antibodies
  • neuroinflammation
  • neurotransmitter modulation
  • synaptic plasticity

Work with this paper

Most-cited papers in Neuroscience

All highly cited Neuroscience papers

Questions about this paper

How do I cite this paper in APA style?

Verma, M., & Singh, N. K. (2026). From bench to bedside: Emerging therapeutics for alzheimer's disease in clinical trials. Metabolic Brain Disease, 41(1). https://doi.org/10.1007/s11011-026-01793-0

How many times has this paper been cited?

0 times, according to OpenAlex on 15 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Mansi Verma, Niraj Kumar Singh.

What is the DOI of this paper?

10.1007/s11011-026-01793-0. The permanent link is https://doi.org/10.1007/s11011-026-01793-0.

Bibliographic data from OpenAlex (CC0), last checked 15 November 2026. ResearchGuru does not host this paper; the links go to the publisher or the repository that does.